⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NBIX News
Neurocrine Biosciences Inc
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight
prnewswire.com
NBIX
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
prnewswire.com
NBIX
Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth
globenewswire.com
PFE
TEVA
NBIX
ALNY
IONS
NVS
QURE
SANG
PTC
WVE
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
prnewswire.com
ACRS
ALC
AMGN
BCRX
BIIB
BMY
CRSP
CTRA
CYTK
DASH
EXAS
GILD
GSK
INCY
JNJ
KDP
LULU
MRNA
NBIX
NVS
OCGN
ORCL
PFE
REGN
ROST
RVMD
SNOW
SRPT
STRL
TGTX
TMO
TRMB
TSLA
TXG
VRTX
XOM
ZBRA
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
globenewswire.com
SVRA
NBIX
JNJ
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
prnewswire.com
NBIX
Global Neurodegenerative Disease Market is Expected to Showcase Significant Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
NVO
LLY
BMY
AXSM
JNJ
SNY
BIIB
ABBV
MRK
REGN
GILD
AMGN
AZN
TEVA
BHC
ALKS
VRTX
SRPT
CRIS
NTLA
EDIT
INCY
ACAD
ALNY
CYTK
IONS
EXAS
IDXX
VNDA
SUPN
RGNX
XOM
CVAC
BNTX
ARCT
MRNA
NBIX
ADPT
AVXL
IMUX
PRGS
RDNT
CRDF
ADSK
ANAB
ATRC
CLDX
CPRX
ESPR
EXEL
FGEN
GALT
GRFS
HRMY
IGC
INSM
KODK
LAKE
LCTX
LEXX
LPCN
MESO
MITK
MNKD
MSFT
MYGN
NEO
NVCR
NXPI
OCGN
OMER
ORCL
PACB
PFE
PLRX
PRGO
PSNL
PTGX
QGEN
RARE
ROST
RVMD
SEIC
SIGA
SMCI
SNOW
SOFI
SPRO
TGTX
TNDM
TXG
ULTA
VEEV
VKTX
VRNS
WVE
XRAY
ZBRA
ZNTL
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
prnewswire.com
NBIX